Live webcast fireside chat on Thursday, December 4th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced JD Finley, Chief Executive Officer and Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, will participate in a fireside chat at the Piper San ...

Group 1 - Atai Beckley NV (NASDAQ:ATAI) is considered one of the most oversold biotech stocks, with H.C. Wainwright reaffirming a Buy rating and a $15 price target following the third-quarter report [1] - The company’s BPL-003 received Breakthrough Therapy Designation (BTD) for treatment-resistant depression, which is a significant milestone [1][2] - The merger between Atai Life Sciences and Beckley Psytech has been concluded, and shareholders approved the acquisition [3] Group 2 - The Phase 2b clinical trial for BPL-003 showed promising results, with a 12 mg dose administered eight weeks after the original dose leading to accelerated antidepressant effects lasting up to eight weeks [2] - Atai Beckley NV is focused on developing innovative treatments for mental health disorders, including depression, anxiety, and substance use disorders [4] - The company is planning a redomiciliation in Delaware and has filed a proposal for the resale of up to 5.3 million shares related to the acquisition of Beckley Psytech [3]

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market Perform to Outperform with a $34 price target. The rating upgrade comes despite Agios’ conflicting topline data for its Phase 3 RISE UP trial assessing mitapivat in sickle cell disease (SCD). The trial reached its primary goal, with 40.6% of patients receiving mitapivat demonstrating a 1.0 g/dL or higher increa ...

Core Insights - Apellis Pharmaceuticals Inc. is considered one of the most oversold biotech stocks to invest in, with a Neutral rating maintained by Mizuho and a price target reduction from $24 to $19 [1] Financial Performance - In Q3 2025, Syfovre's revenue was $150.9 million, slightly down from $152.0 million in Q3 2024, but there was a 4% quarter-over-quarter increase in injections [2] - Apellis Pharmaceuticals reported that Syfovre holds over 60% market share in the geographic atrophy (GA) treatment area, with 52% of new patient starts in Q3 2025 [2] - Mizuho has lowered its revenue projections for Syfovre, now estimating a peak annual revenue of about $800 million, which is 25-30% lower than consensus estimates [2] Company Overview - Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic compounds for diseases with high unmet needs [2]

Core Insights - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as one of the most oversold biotech stocks, reporting third-quarter adjusted earnings of $0.47 per share, significantly above analyst expectations of $0.05 per share, with revenue reaching $66 million [1][2]. Financial Performance - The company reported adjusted earnings of $0.47 per share for Q3, surpassing the consensus estimate of $0.05 per share [1]. - Revenue for the quarter was $66 million, which also exceeded analyst expectations [1]. Stock Performance and Market Reaction - Despite strong financial results, the stock price fell sharply due to investor concerns regarding the discontinuation rates for VYKAT XR, a treatment for hyperphagia in patients with Prader-Willi syndrome [2]. - Piper Sandler reaffirmed an Overweight rating and a price target of $145 for Soleno Therapeutics, suggesting that the stock had been oversold due to recent safety concerns related to VYKAT XR [3]. Analyst Opinions - Piper Sandler maintained optimism regarding the ongoing launch of VYKAT XR, viewing the stock's decline as a "compelling buying opportunity" for investors [4]. - The firm attributed the stock's decline to safety concerns raised in the FDA Adverse Event Reporting System and a brief thesis published in August [3]. Company Overview - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases [4].

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 25, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than Janua ...

Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀PETACH TIKVA, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will participate in a virtual Key Opinion Leader (KOL) event hosted by ROTH Capital Partners. KOL Event Informat ...

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight the impact of depression and burden of titration on patients with epilepsy, as well as new pre-clinical data from the Company’s NaV1.1 program in Dravet syndrome VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biophar ...

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The study, supported by a grant from the ALS Association, wil ...

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/ ...